The further positive data from the DREAMM-1 study, which is based on results of the pre-specified interim analysis, showed the durability and depth of response of GSK2857916 anti-BCMA
The collaboration, originally announced in February 2015, is focused on discovering, developing and commercializing novel biologic therapeutics across a wide range of therapeutic areas. Under the terms of
Pfizer has paid around €45m ($51m) to purchase a 15% equity interest in Vivet Therapeutics, and will pay up to €560m that includes option exercise payment and certain
The alliance has notified health authorities and trial investigators of the decision to discontinue the trial. The decision was based on several emerging factors since the trial’s initiation,
Zulresso is claimed to be the first and only medicine secured approval to treat PPD, which is the most common medical complication of childbirth. The medicine is an
Under the agreement, twoXAR will use its proprietary artificial intelligence (AI ) technology to identify a set of lead compounds which demonstrate a novel mechanism of action and
Tecentriq monoclonal antibody has been approved in combination with carboplatin and etoposide as a first-line treatment for adults with ES-SCLC. The approval was based on data from the
Extensive blistering can lead to serious, life-threatening fluid loss, infection and/or death. MabThera is the first biologic therapy approved by the European Commission for PV and the first
Based in Tokyo, Ayumi is engaged in the manufacturing and marketing of various drug products for anti-rheumatism and orthopedic pain management. Citing a person familiar with the matter,
Under The collaboration agreement will enable Merck to use Iktos generative modelling AI technology to facilitate the rapid and cost-effective discovery and design of new compounds. The agreement
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.